

Jurisdiction Specific Medicare Part B

Rituximab products

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Rituxan	rituximab
Riabni	rituximab-arxx
Ruxience	rituximab-pvvr
Truxima	rituximab-abbs

Covered Uses

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- Non-Hodgkin's lymphoma (NHL)
- Chronic lymphocytic leukemia (CLL)
- Rheumatoid arthritis
- Granulomatosis with polyangiitis (GPA)
- Microscopic polyangiitis (MPA)
- Pemphigus vulgaris (PV)
- Prior to autologous stem cell rescue
- Immune or idiopathic thrombocytopenia purpura
- Evans syndrome
- Waldenstrom's macroglobulinemia
- Thrombotic thrombocytic purpura (TTP)
- Autoimmune hemolytic anemia
- Multifocal motor neuropathy (MMN)

Rituximab products MedB Jurisdiction J (AL GA TN) Jurisdiction M (NC SC VA WV) 4452-A P2025.docx© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

- Relapsing-remitting multiple sclerosis
- Neuromyelitis optica
- Polymyositis
- Myasthenia gravis
- Anti-myelin associated glycoprotein (anti-MAG) polyneuropathy
- Graft-versus-host disease (GVHD)
- Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis
- Cryoglobulinemia and cryoglobulinemia-induced renal disease
- Post-transplant lymphoproliferative disorder (PTLD)
- Epstein-Barr viremia
- Autoimmune encephalitis

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

Coverage Criteria

Non-Hodgkin's lymphoma^{1,2}

Authorization of 12 months may be granted for treatment of non-Hodgkin's lymphoma (NHL) when any of the following criteria is met:

- Member has relapsed or refractory low-grade or follicular CD20-positive B-cell NHL and rituximab will be used as a single agent
- Member has previously untreated follicular CD20-positive B-cell NHL in combination with first-line chemotherapy
- Single-agent maintenance therapy in members who achieved a complete or partial response to rituximab in combination with chemotherapy
- Member has non-progressing (including stable disease), low-grade, CD20-positive NHL and rituximab will be used as a single agent after first-line CVP chemotherapy
- Rituximab will be used for treatment of previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or other anthracycline-based chemotherapy regimens
- Rituximab will be used as re-induction treatment appropriate for responders and members with stable low-grade or follicular CD20-positive B-cell NHL
- Member has intermediate or high-grade NHL and rituximab will be used in one of the following regimens:
 - Single agent
 - In combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
 - In combination with other agents active against the disease

Rituximab products MedB Jurisdiction J (AL GA TN) Jurisdiction M (NC SC VA WV) 4452-A P2025.docx© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Chronic lymphocytic leukemia^{1,2}

Authorization of 12 months may be granted for treatment of chronic lymphocytic leukemia (CLL) when both of the following criteria are met:

- Member has either previously untreated or previously treated CD20-positive CLL
- Rituximab will be used in combination with fludarabine and cyclophosphamide

Rheumatoid arthritis^{1,2}

Authorization of 12 months may be granted for treatment of adults with moderate to severely active rheumatoid arthritis when both of the following criteria are met:

- Rituximab will be used in combination with methotrexate
- Member has tried and had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies

Granulomatosis With polyangiitis and microscopic polyangiitis^{1,2}

Authorization of 12 months may be granted for treatment of granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA) when rituximab will be used in combination with glucocorticoids.

Pemphigus vulgaris³

Authorization of 12 months may be granted for treatment of moderate to severe pemphigus vulgaris.

Prior to autologous stem cell rescue^{1,2}

Authorization of 12 months may be granted prior to autologous stem cell rescue when both of the following criteria are met:

- Rituximab will be used as second-line or salvage therapy for progressive or relapsed disease with or without radiation therapy
- Member was initially treated with chemotherapy with or without radiation therapy in combination with bendamustine

Immune or idiopathic thrombocytopenia purpura^{1,2}

Authorization of 12 months may be granted for treatment of immune or idiopathic thrombocytopenia purpura.

Evans syndrome^{1,2}

Authorization of 12 months may be granted for treatment of Evans' syndrome.

Rituximab products MedB Jurisdiction J (AL GA TN) Jurisdiction M (NC SC VA WV) 4452-A P2025.docx© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Waldenstrom's macroglobulinemia^{1,2}

Authorization of 12 months may be granted for treatment of Waldenstrom's macroglobulinemia.

Thrombotic thrombocytopenic purpura (TTP)^{1,2}

Authorization of 12 months may be granted for treatment of refractory thrombotic thrombocytopenic purpura if the member did not respond to plasmapheresis.

Autoimmune hemolytic anemia^{1,2}

Authorization of 12 months may be granted for treatment of autoimmune hemolytic anemia when the disease is refractory to conventional treatment (e.g., corticosteroid treatment and splenectomy).

Multifocal motor neuropathy^{1,2}

Authorization of 12 months may be granted for treatment of multifocal motor neuropathy (MMN) when rituximab will be used as a second-line therapy.

Multiple sclerosis^{1,2}

Authorization of 12 months may be granted for treatment of relapsing-remitting multiple sclerosis (RRMS) when rituximab will be used as a third-line therapy.

Neuromyelitis optica^{1,2}

Authorization of 12 months may be granted for treatment of neuromyelitis optica.

Polymyositis^{1,2}

Authorization of 12 months may be granted for treatment of polymyositis when rituximab will be used as a second- or third-line therapy.

Myasthenia gravis^{1,2}

Authorization of 12 months may be granted for treatment of myasthenia gravis.

Anti-myelin associated glycoprotein (anti-MAG) polyneuropathy^{1,2}

Authorization of 12 months may be granted for treatment of anti-myelin associated glycoprotein (anti-MAG) polyneuropathy.

Graft-versus-host disease^{1,2}

Authorization of 12 months may be granted for treatment of graft-versus-host disease when rituximab will be used as third-line therapy or greater.

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis^{1,2}

Authorization of 12 months may be granted for treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Cryoglobulinemia^{1,2}

Authorization of 12 months may be granted for treatment of cryoglobulinemia and cryoglobulinemia-induced renal disease.

Post-transplant lymphoproliferative disorder^{1,2}

Authorization of 12 months may be granted for treatment of post-transplant lymphoproliferative disorder (PTLD).

Epstein-Barr viremia^{1,2}

Authorization of 12 months may be granted for the prevention of Epstein-Barr viremia when all of the following criteria are met:

- The member is at high risk for post-transplant lymphoproliferative disease
- The member has undergone an allogenic bone marrow transplant and will have prolonged T-cell impairment
- Member must have received one of the following treatments:
 - Cord blood units or ex vivo CD34 selected or T-cell depleted hematopoietic cell grafts
 - Anti T-cell antibodies (alemtuzumab)
 - High-dose steroids for treatment of severe acute graft-versus-host disease

Autoimmune encephalitis^{1,2}

Authorization of 12 months may be granted for treatment of autoimmune encephalitis in bone marrow transplant patients.

References

1. Rituximab LCD (L35026) Version R27. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed April 15, 2025.

Rituximab products MedB Jurisdiction J (AL GA TN) Jurisdiction M (NC SC VA WV) 4452-A P2025.docx© 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s)
4452-A

2. Billing and Coding: Rituximab (A56380) Version R20. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed April 15, 2025.
3. Rituxan [package insert]. South San Francisco, CA: Genentech, Inc; December 2021.
4. Truxima [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; February 2022.
5. Ruxience [package insert]. NY, NY: Pfizer Biosimilars; October 2023.
6. Riabni [package insert]. Thousand Oaks, CA: Amgen Inc.; February 2023.